Exclusive Summary

• Highly recognized in clinical practice and explicitly recommended by international guidelines (e.g., EASL) for hyperammonemia and hepatic encephalopathy.
• The originator's patent (Hepa-Merz) has long expired, offering completely zero IP risk and enabling fast-track registration and commercialization for overseas distributors.
• Targets a massive global patient base, with 30%-45% of the estimated 112 million liver cirrhosis patients developing hepatic encephalopathy, indicating rigid market demand.
• Backed by China's integrated API-to-FDF supply chain, the product offers significant cost advantages, ensuring highly attractive profit margins for regional distributors.